Ceramide(d18:1/18:1)-NDUFA6 interaction inactivates respiratory complex I to attenuate oxidative-stress-driven pathogenesis in liver ischemia/reperfusion injury
Kai Wang, … , Yiyi Li, Chuanjiang Li
Kai Wang, … , Yiyi Li, Chuanjiang Li
Published April 17, 2025
Citation Information: JCI Insight. 2025;10(10):e187083. https://doi.org/10.1172/jci.insight.187083.
View: Text | PDF
Research Article Hepatology Metabolism

Ceramide(d18:1/18:1)-NDUFA6 interaction inactivates respiratory complex I to attenuate oxidative-stress-driven pathogenesis in liver ischemia/reperfusion injury

Abstract

Oxidative stress driven by malfunctioning respiratory complex I (RC-I) is a crucial pathogenic factor in liver ischemia/reperfusion (I/R) injury. This study investigated the role of alkaline ceramidase 3 (ACER3) and its unsaturated long-chain ceramide (CER) substrates in regulating liver I/R injury through RC-I. Our findings demonstrated that I/R upregulated ACER3 and decreased unsaturated long-chain CER levels in human and mouse livers. Both global and hepatocyte-specific Acer3 ablation, as well as treatment with CER(d18:1/18:1), led to a significant increase in CER(d18:1/18:1) levels in the liver, which mitigated the I/R-induced hepatocyte damage and inflammation in mice. Mechanistically, ACER3 modulated CER(d18:1/18:1) levels in mitochondria-associated membranes and the endoplasmic reticulum (ER), thereby influencing the transport of CER(d18:1/18:1) from the ER to mitochondria. Acer3 ablation and CER(d18:1/18:1) treatment elevated CER(d18:1/18:1) in mitochondria, where CER(d18:1/18:1) bound to the RC-I subunit NDUFA6 to inactivate RC-I and reduced reactive oxygen species production in the I/R-injured mouse liver. These findings underscore the role of the CER(d18:1/18:1)-NDUFA6 interaction in suppressing RC-I–mediated oxidative-stress-driven pathogenesis in liver I/R injury.

Authors

Kai Wang, Leyi Liao, Hanbiao Liang, Pengxiang Huang, Qingping Li, Baoxiong Zhuang, Chen Xie, Xiangyue Mo, Xuesong Deng, Jieyuan Li, Yang Lei, Minghui Zeng, Cungui Mao, Ruijuan Xu, Cuiting Liu, Xianqiu Wu, Jie Zhou, Biao Wang, Yiyi Li, Chuanjiang Li

×

Figure 3

CER(d18:1/18:1) treatment attenuates liver I/R injury.

Options: View larger image (or click on image) Download as PowerPoint
CER(d18:1/18:1) treatment attenuates liver I/R injury. (A) Schematic of ...
(A) Schematic of the experimental design for CER(d18:1/18:1) treatment in male mice subjected to I/R injury. C57BL/6J wild-type mice were intraperitoneally treated with CER(d18:1/18:1) (5 mg/kg BW, once per day) before and after I/R injury. (B and C) CER(d18:1/18:1) levels (B) and other CER levels (C) in the vehicle- and CER(d18:1/18:1)-treated mice after sham operation and at 6 hours after I/R (n = 3). (D and E) Serum ALT (D) and AST (E) levels in the vehicle- and CER(d18:1/18:1)-treated mice after sham operation and at 6 hours and 24 hours after I/R (n = 6). (F and G) Representative H&E staining of liver sections, with circled areas indicating necrotic foci (F), and quantification of necrotic area (G) in the vehicle- and CER(d18:1/18:1)-treated mice after sham operation and at 6 hours and 24 hours after I/R (n = 6). (H–L) Relative mRNA levels of proinflammatory cytokines Il-6 (H) and Tnf-α (I) and neutrophil markers Ly6g (J) and Mpo (K) in liver tissues from vehicle- and CER(d18:1/18:1)-treated mice after sham operation and at 6 hours and 24 hours after I/R. (L) Representative Ly6G staining of liver sections, with black arrows indicating inflammatory infiltration after sham operation and at 6 hours and 24 hours after I/R (n = 5). Scale bars: 100 μm. Data in B–E and G–K are expressed as mean ± SD. Statistical significance was determined using 2-tailed Student’s t test (B and C) or 1-way ANOVA followed by Tukey’s test for multiple comparisons (D–E and G–K). *P < 0.05; **P < 0.01; ***P < 0.001. #P < 0.05, ###P < 0.001 for comparisons between sham and I/R (D, E, and G–K).